Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Wells et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69da2667a6045d71bfa3c3fc — DOI: https://doi.org/10.1200/jco.2011.35.5040

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer· 2010 · 516 citations
2. Somatic mutations in the <i>RET</i> proto‐oncogene in sporadic medullary thyroid carcinoma· 1996 · 278 citations
3. Regression Models and Life-Tables· 1992 · 26,652 citations
4. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients· 1998 · 569 citations
5. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A· 1993 · 1,960 citations